{{Rsnum
|rsid=12980275
|Chromosome=19
|position=39241143
|Orientation=plus
|GMAF=0.314
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 54.9 | 36.3 | 8.8
| HCB | 85.4 | 14.6 | 0.0
| JPT | 74.3 | 23.0 | 2.7
| YRI | 20.4 | 47.6 | 32.0
| ASW | 17.9 | 50.0 | 32.1
| CHB | 85.4 | 14.6 | 0.0
| CHD | 87.2 | 11.9 | 0.9
| GIH | 60.4 | 33.7 | 5.9
| LWK | 28.2 | 54.5 | 17.3
| MEX | 29.3 | 56.9 | 13.8
| MKK | 25.6 | 50.0 | 24.4
| TSI | 33.3 | 52.9 | 13.7
| HapMapRevision=28
}}[http://blog.23andme.com/2009/09/18/snpwatch-more-evidence-that-genetic-variations-are-important-for-hepatitis-c-infection-and-treatment/ 23andMe blog] 

[[rs8099917]](C) less likely to respond to [[Hepatitis C]] treatment. 

[[rs12979860]](C;C) better able to become naturally [[Hepatitis C]] virus-free.
[[rs12980275]](A)  usually corresponds to the [[rs12979860]](C)

{{PMID Auto
|PMID=19749757
|Title=Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
}}

{{omim
|desc=INTERLEUKIN 28B; IL28B
|id=607402
|rsnum=12980275
}}

{{PharmGKB
|RSID=rs12980275
|Name_s=
|Gene_s=IL28B
|Feature=
|Evidence=PubMed ID:19749757
|Annotation=Risk or phenotype-associated allele: G. Phenotype: This variant is associated with null virological response (NVR) and sustained virologic response (SVR) in Janapese patients with hepatitis C virus infection treated with PEG-INF-alpha plus ribavirin. Study size: Initial sample:154; Replication Sample: 172. Study population/ethnicity: Japanese. Significance metric(s): P=1.6x10-13 (NVR); P = 3.99 x 10(-24)(SVR). Type of association: GN; CO
|Drugs=interferon alfa-2a, recombinant; ribavirin
|Drug Classes=
|Diseases=Hepatitis C; Hepatitis C, Chronic
|Curation Level=Curated
|PharmGKB Accession ID=PA165260378
}}

{{omim
|id=609532
|rsnum=12980275
}}

{{PMID Auto
|PMID=21390311
|Title=Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms
|OA=1
}}

{{PMID Auto
|PMID=21987611
|Title=IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients
|OA=1
}}

{{PMID Auto
|PMID=22118055
|Title=Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy
}}

{{PMID Auto
|PMID=22234924
|Title=Combined effects of different IL28B gene variants on the outcome of dual combination therapy in chronic HCV type 1 infection
}}

{{PMID Auto
|PMID=22253715
|Title=Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3
|OA=1
}}

{{PMID Auto
|PMID=22108195
|Title=Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B
}}

{{PMID Auto
|PMID=22649509
|Title=IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population
|OA=1
}}

{{PMID Auto
|PMID=22329371
|Title=IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection
}}

{{PMID Auto GWAS
|PMID=22497812
|Trait=None
|Title=Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.
|RiskAllele=
|Pval=5E-17
|OR=None
|ORtxt=None
|OA=1
}}

{{PMID|20708617}} Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

{{PMID|21112657}} Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.

{{PMID|21112660}} Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

{{PMID|21274371|OA=1
}} Peginterferon and ribavirin treatment for hepatitis C virus infection.

{{PMID|21354446}} IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.

{{PMID|21443535}} IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

{{PMID|22310928}} Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12980275
|overall_frequency_n=45
|overall_frequency_d=126
|overall_frequency=0.357143
|n_genomes=33
|n_genomes_annotated=0
|n_haplomes=43
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23103287
|Title=IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus.
}}

{{PMID Auto
|PMID=23135173
|Title=Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.
}}

{{PMID Auto
|PMID=23314745
|Title=Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
|OA=1
}}

{{PMID Auto
|PMID=23565619
|Title=IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients.
}}

{{PMID Auto
|PMID=24999753
|Title=Interleukin 28B Polymorphisms and Therapy Response in Egyptian Hepatitis C Genotype-4 Patients
}}

{{PMID Auto
|PMID=25032184
|Title=No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}